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Ascorbic acidFibroblast growth factor receptor 1 (Fgfr1) gene knockout impairs cardiomyocyte differentiation in murine
embryonic stem cells (mESC). Here, various chemical compounds able to enhance cardiomyocyte differenti-
ation in mESC [including dimethylsulfoxide, ascorbic acid (vitC), free radicals and reactive oxygen species]
were tested for their ability to rescue the cardiomyogenic potential of Fgfr1−/− mESC. Among them, only
the reduced form of vitC, L-ascorbic acid, was able to recover beating cell differentiation in Fgfr1−/− mESC.
The appearance of contracting cells was paralleled by the expression of early and late cardiac gene markers,
thus suggesting their identity as cardiomyocytes. In the attempt to elucidate the mechanism of action of vitC
on Fgfr1−/− mESC, we analyzed several parameters related to the intracellular redox state, such as reactive
oxygen species content, Nox4 expression, and superoxide dismutase activity. The results did not show any re-
lationship between the antioxidant capacity of vitC and cardiomyocyte differentiation in Fgfr1−/− mESC. No
correlation was found also for the ability of vitC to modulate the expression of pluripotency genes. Then, we
tested the hypothesis that vitC was acting as a prolyl hydroxylase cofactor by maintaining iron in a reduced
state. We ﬁrst analyze hypoxia inducible factor (HIF)-1α mRNA and protein levels that were found to be
slightly upregulated in Fgfr1−/− cells. We treated mESC with Fe2+ or the HIF inhibitor CAY10585 during the
ﬁrst phases of the differentiationprocess and, similar to vitC, the two compoundswere able to rescue cardiomyocyte
formation in Fgfr1−/−mESC, thus implicating HIF-1αmodulation in Fgfr1-dependent cardiomyogenesis.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The Fibroblast Growth Factor (FGF) family is composed by at least
22 structurally related polypeptides implicated in a variety of physio-
logical and pathological conditions, including embryonic develop-
ment, tissue growth and remodeling, inﬂammation, tumor growth
and vascularization [1,2]. FGFs mediate their biological responses by
binding to cell surface high afﬁnity tyrosine kinase (TK) FGF receptors
(FGFRs), designated FGFR-1 to ‐4 [3]. FGFRs are composed of an extra-
cellular portion consisting of three immunoglobulin (Ig)-like domains
(D1, D2, and D3), a hydrophobic transmembrane region, and a cytoplas-
mic TK tail. The ligand binding site for FGFs is located in the Ig-like do-
mains D2–D3 and the linker that connects them [4]. FGF/FGFR signaling
plays important functions in mesoderm formation and development [5].
Accordingly, Fgfr1−/− mice die during gastrulation, displaying defectiveUnit, Department of Biomedical
uropa, 11, 25123 Brescia, Italy.
era@gmail.com (P. Dell'Era).
land.
l rights reserved.mesoderm patterning with reduction in the amount of paraxial meso-
derm and lack of somite formation [6,7]. Studies on chimeric embryos
using FGFR1-deﬁcient embryonic stem (ES) cells revealed an early defect
in themesodermal and endodermal cellmovement through the primitive
streak, followed by deﬁciencies in contributing to anterior mesoderm, in-
cluding heart tissue [8,9].
Pluripotent murine embryonic stem cells (mESC) originate from
the inner cell mass of the blastocyst and are capable of cell renewal
and differentiation after in vitro aggregation into three-dimensional
structures termed embryoid bodies (EBs) [10]. EBs generate deriva-
tives of all three primary germ layers, including cardiomyocytes that
are manifested by the appearance of spontaneously contracting foci
[10]. The cardiogenic differentiation of mESC has been extensively
studied because of their potential in regenerative medicine. Indeed,
mESC-based cell therapy is a promising approach for the treatment
of impaired myocardial function and provides promising results com-
pared to other cell types [11]. To this respect, in order to enhance the
efﬁciency of mESC differentiation toward a cardiomyogenic pheno-
type, modulation of cardiomyocyte differentiation has been achieved
by treating mESC with various cytokines, growth factors, and synthet-
ic chemical compounds, including dimethylsulfoxide, retinoic acid, or
141E. Crescini et al. / Biochimica et Biophysica Acta 1833 (2013) 140–147ascorbic acid (vitC) [12]. Indeed, vitC enhances differentiation of ESC
into cardiac myocytes [13], promotes the proliferation of cardiac pro-
genitor cells [14], improves cardiomyoblast survival and promotes
neovascularization in bioartiﬁcial grafts [15].
The isoform IIIc of FGFR1 has been implicated in cardiomyocyte
development during EBS differentiation [16]. Indeed, Fgfr1+/− and
Fgfr1−/− mESC are morphologically indistinguishable, have similar
growth rates in vitro, and can generate muscle cells when injected
in nude mice to form teratomas [7]. Nevertheless, analysis of the in
vitro differentiation process of the two cell lines following EBS forma-
tion demonstrates a non-redundant role for Fgfr1 in cardiomyocyte
development [16]. Accordingly, the expression of Fgfr1 is strictly re-
quired to up-regulate Nkx2.5, one of the ﬁrst transcription factors
that will guide differentiating mESC toward the cardiac lineage [16].
Here we show that the inhibitory effect of Fgfr1 knockout on car-
diomyocyte differentiation can be overcome by treating mESC with
vitC, Fe2+, or the hypoxia inducible factor (HIF) inhibitor CAY10858.
Taken together our data suggest that the cardiomyogenic property of
vitC in Fgfr1−/−mESC system is related to its activity as a prolyl hydrox-
ylase cofactor, thus implicating HIF-1αmodulation in Fgfr1-dependent
cardiomyogenesis.
2. Materials and methods
2.1. Chemicals
L-Ascorbic Acid (vitC), 5-Azacytidine (AZA), S-Nitroso-N-Acetyl-DL-
Penicillamine (SNAP), N,N-Diethylaniline (DEA), Retinoic Acid (RA),
Dimethyl-sulfoxide (DMSO), α-tocopherol (VitE), Sodium metabisulﬁte
(Na2S2O5), N-Acetyl-L-Cysteine (NAC), L-Glutathione (GSH), N6,2′-O-
dibutyryladenosine 3′,5′ cyclic monophosphate (db-cAMP), Iron(II) chlo-
ride (FeCl2), and Dehydroascorbic acid (DHA) were from Sigma-Aldrich.
The HIF-1α inhibitor CAY10585 [17] was from Cayman Chemical.
2.2. Cell culture
Murine R1 mESC [7,16] were adapted to grow without feeder cells
and maintained in DMEM supplemented with 15% fetal bovine serum
(Hyclone), 0.1mmol/L non essential amino acids, 1mmol/L sodium
pyruvate, 0.1mmol/L b-mercaptoethanol, 2mmol/L L-glutamine, and
1000U/mL LIF (ESGRO, Chemicon).
At T0 of differentiation, (differentiation day 0, DD0), exponentially
growing mESC were resuspended in LIF-deprived (EBS) medium and
cultured in 30μL hanging drops (400 cells) for 2days to allow cell aggre-
gation. Then, aggregateswere transferred onto 0.5% agarose-coated dis-
hes and grown for 5days in EBS medium. At DD7, EBs were transferred
into 24-well tissue culture plates and allowed to adhere. Aggregates
were monitored for the appearance of spontaneously contracting foci
during the following days. The treatments with the different com-
pounds were started at DD0.
2.3. RNA extraction, semi-quantitative, and quantitative RT-PCR analysis
Total RNA was extracted from mESC as described [18]. Contami-
nating DNAwas digested using DNAse, following indications reported
in RNeasy® Micro Handbook (Qiagen). Two micrograms of total RNA
was retrotranscribed with MMLV reverse transcriptase (InVitrogen)
using random hexaprimers in a ﬁnal 20μL volume. For semiquantita-
tive PCR, 2μL of the retrotranscribed RNA were subjected to polymer-
ase chain reaction (PCR) using REDTaq® ReadyMix™ PCR Reaction
Mix (Sigma). Oligonucleotide primers and PCR conditions were de-
scribed previously [16]. The data were conﬁrmed by analyzing RNA
extracted from two or more independent differentiation experiments.
Quantitative PCR (qPCR) was performed with a Biorad iCycler iQ™
Real-Time PCR Detection System using a iQ™ SYBR Green Supermix
(Biorad) according to manufacturer's instructions. The qPCR speciﬁcprimers (ﬁnal concentration 400nM) were as follows: Nkx2.5 forward
(for) primer: 5′-CCAAGTGCTCTCCTGCTTTC; reverse (rev) primer: 5′-
GTCCAGCTCCACTGCCTTCT; Myl2 for: 5′-AAAGAGGCTCCAGGTCCAAT;
rev: 5′-CTGGTCGATCTCCTCTTTGG; Tubulin for: 5′-CCGGACAGTGTGG
CAACCAGATCGG; rev: 5′-TGGCCAAAAGGACCTGAGCGAACGG; Vcam1
for: 5′-GAACTGATTATCCAAGTCTCTCCA; rev: 5′-CCATGTCTCCTGTCTTT
GCTT; Brachyury(T) for: 5′-GAACCTCGGATTCACATCGT; rev: 5′-TTCTTT
GGCATCAAGGAAGG; Nox4 for: 5′-TGTTGGGCCTAGGATTGTGTT; rev:
5′-AGGGACCTTCTGTGATCCTCG; Oct4 for: 5′-GACCGCCCCAATGCCGTG
AA; rev: 5′-GGGCTTTCATGTCCTGGGACTCC; Nanog for: 5′-CCTTCCCTC
GCCATCACACTGACA; rev: 5′-GAGGAAGGGCGAGGAGAGGCAGC; Sox2
for: 5′-CAAGGCAGAGAAGAGAGTGTTTGCA; rev: 5′-GCCGCCGCGATTGTT
GTGAT; Klf4 for: 5′-TTCTCCACGTTCGCGTCCGG; rev: 5′-ACGCCAACGGT
TAGTCGGGGC. HIF-1α for: 5′-TGCTCATCAGTTGCCACTTC; rev: 5′-CCATC
TGTGCCTTCATCTCA. Gene expression levels were evaluated by compar-
ing differentiated cells to the corresponding undifferentiated cells. Data
were analyzed using REST [19].
2.4. Whole mount in situ hybridization
Total RNA from Fgfr1+/− EBs at DD10 was reverse transcribed to
cDNA and used as templates for PCR reactions using the following oligo-
nucleotide primers: Myl2 for: 5′-GCCAAGAAGCGGATAGAAGG; rev:
5′-CTGTGGTTCAGGGCTCAGTC; Cdh5 for: 5′-TTTGGAATCAAATGCACA
TCGA; rev: 5′-TGCTGTACTTGGTCATCCGGTT. Fragments were subcloned
into pCR®II-TOPO® vector (inVitrogen). The plasmids were linearized
andused as template for RNA synthesiswith T7 or SP6 polymerase for an-
tisense and sense control probes in thepresence of digoxigenin-11-UTP
by using DIG RNA labeling kit (Roche Diagnostics).
At DD9 EBs were ﬁxed overnight in 4% paraformaldehyde (PFA) in
phosphate-buffered saline (PBS), dehydrated with methanol 100%
and stored at −20°C until hybridization. Fixed EBs were rehydrated
and rinsed twice in PBT (PBS, 0.1% Tween®20), then digested with
proteinase K (10μg/mL in PBT) for 15min at room temperature,
followed by incubation in 4% PFA in PBS for 20min. EBs were subse-
quently rinsed twice in PBT for 5min and pre-hybridized at 65°C in
hybridization mix (HM: 50% formamide, 5× SSC, 10mM citric acid
pH 6, 0.1% Tween® 20, 50μg/mL heparin, 50μg/mL tRNA) for 2h. EBs
were then incubated overnight at 65°C in HM containing 1mg/mL of de-
natured riboprobe. On the second day, EBs were sequentially washed in
2× SSC containing 75%, 50%, 25%, and 0% of hybrizidationwashmix (50%
formamide, 5× SSC, 10mM citric acid pH 6, 0.1% Tween® 20) at 65°C for
15min each, followed by three washes with 0.2× SSC at 65°C for 30min.
EBs were then rinsed at room temperature with increasing concentra-
tion of PBT (25%, 50%, and 75% respectively) in 0.2× SSC, 10min each, in-
cubated in blocking buffer (BB: 2% sheep serum, 2mg/mL BSA in PBT) for
3h, and immunodecorated overnight at 4°C in BB containing 1:10,000
alkaline phosphatase-coupled anti-Digoxigenin antibody (Roche Diag-
nostics). On the following day EBs were extensively washed with
PBT and the reaction was developed in staining solution [100mM
Tris HCl pH 9.5, 50mM MgCl2, 100mM NaCl, 0.1% Tween® 20,
500mM Tetramisole, NBT and BCIP (Roche Diagnostics)]. Hybridized
EBs were post-ﬁxed for 20min in 4% PFA in PBS and subsequently
dehydrated and included in parafﬁn. 7μm sections were cut, mounted
with DPX (Fluka), observed and photographed under a Zeiss Axiovert
200Mmicroscope.
2.5. Immunostaining of EBs
At DD9 EBs in suspension were ﬁxed overnight in PBS-diluted 4%
PFA, dehydrated with methanol and stored at −20°C until immuno-
staining. Fixed EBs were rinsed three times in Tris/HCl pH 8.2, 150mM
NaCl (TBS) and blocked in 3% Normal serum (determined by host spe-
cies for secondary antibody) in TBS/TNB with 0,3% Triton-X (TBS++)
for 2h at room temperature. EBs were incubated with primary mouse
anti-actin (α-sarcomeric) monoclonal antibody (Sigma Aldrich) in
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were rinsed in TBS for three times, 15min each and incubated in
TBS++once for 1h at room temperature. EBswere incubatedwith sec-
ondary goat FITC-conjugated anti-mouse IgM (μ-chain speciﬁc) (Sigma
Aldrich). EBs were rinsed in TBS for three times, 15min each, washed in
DAPI-containing TBS for 10min and rinsed four times in TBS 15min each.
EBs were mounted with Dako Fluorescence Mounting Medium (DAKO)
and then photographed under a Zeiss Axiovert 200M microscope.
2.6. Measurement of reactive oxygen species (ROS) content
Intracellular ROS levels were measured using the ﬂuorescent dye
2′,7′-dichlorodihydroﬂuorescein diacetate (H2DCF-DA) (Molecular Pro-
bes), a nonpolar compound that is converted into a nonﬂuorescent
polar derivative (H2DCF) by cellular esterases after incorporation into
cells. H2DCF is membrane impermeable and is rapidly oxidized to the
highly ﬂuorescent 2′,7′-DCF (DCF) in the presence of intracellular ROS
[20]. For the experiments, EBs were washed in Hanks' Balanced Salt So-
lution (HBSS, GIBCO) and then incubated in nitrogen-saturated HBSS
with 20μM H2DCF-DA dissolved in DMSO for 30min at 37°C 5%CO2.
Then EBs were washed twice in HBSS, and separated into single-cell
suspension by incubation for 10min at 37°C in Accutase™ (Sigma Al-
drich), rinsed 10min in fetal bovine serum, washed in HBSS and
ﬁltrated through a 40μm Cell Strainers (BD Biosciences). Intracellular
DCF ﬂuorescence, proportional to the amount of ROS, was evaluated
by ﬂow cytometry.
2.7. Superoxide dismutase (SOD) activity
SOD activity was assayed in terms of its ability to inhibit the
radical-mediated chain-propagating autoxidation of epinephrine [21].
EBs were collected and lysed on ice in HNTG buffer (50mM HEPES,
150mM NaCl, 1% Triton X-100, 10% glycerol) containing 1.5mM MgCl2,
1.0mMEGTA. After centrifugation to remove cellular debris, total protein
content was assayed and 10μL of cell lysatewas used for further analysis.
Auto-oxidation of epinephrine was performed in buffer containing
0.05M glycine, 0.1M NaOH and 0.1M NaCl, at pH 10.3 in the presence
or absence of sample or puriﬁed enzyme. The reaction was monitored
in a 96-well plate reader by measuring the decrease of absorbance at
540nm, due to SOD-mediated inhibition of epinephrine oxidation. For
the different samples, SOD units were normalized for total protein con-
tent and expressed as a percentage of SOD activity in undifferentiated
mESC.
2.8. Western blot analysis
Nuclear proteins were isolated from mESC using “Nuclear Extract
Kit” (Active Motif) and quantiﬁed using a Bradford assay (Bio-Rad).
Forty micrograms of nuclear-extracted proteins were denatured in
sample buffer, boiled at 95°C for 5min, fractionated by 7% SDS poly-
acrylamide gel electrophoresis and transferred to polyvinylidene
diﬂuoride (PVDF) membrane (Immobilon-P, Millipore). In order to
assess the uniformity of protein loading, membranes were stained
with 1% amido black solution. Western blot analysis was performed
using an anti-HIF-1α monoclonal antibody (clone H1α67, Millipore)
followed by a HRP-conjugated goat anti-mouse secondary antibody
incubation (Sigma-Aldrich). Immune complexes were visualized
by incubating PVDF with Western Blot Luminol Reagent (Santa
Cruz Biotechnology Inc.) containing 10% of chemiluminescence en-
hancer (Supersignal, Pierce) and exposing the membrane to X-ray
ﬁlm (Pierce). Quantiﬁcation of the bands was performed using
Image Analysis Software ImageJ 1.45s (NIH). Similar results were
obtained by incubating the membrane with a secondary goat
anti-mouse IRDye 800 CW conjugated antibody (LI-COR Biosci-
ence), and quantifying the results using Odyssey® infrared scanner
(LI-COR Bioscience).3. Results
3.1. Ascorbic acid rescues beating foci formation in Fgfr1−/− mESC
Fgfr1 knockdown in the mESC model leads to a strong impairment
in cardiomyocyte development [16]. Previous studies concerning car-
diac differentiation had shown that various extrinsic factors promote
in vitro cardiomyocyte differentiation of mESC, including growth fac-
tor peptides and a number of chemical compounds [22]. On this basis,
Fgfr1−/− mESC were subjected to a standard differentiation protocol
in the presence of various chemicals known to be endowed with car-
diogenic properties. In particular, Fgfr1−/−mESC were treated at DD0
and DD2 with the synthetic nucleoside inhibitor of DNA methylation
5-azacitidine [23], the antioxidative agent vitC or its oxidized form
DHA [13], the cyclic adenosine 3′,5′-monophosphate (cAMP) [24],
the NO donors S-nitroso-N-acetylpenicillamine (SNAP) and 2-(N,
N-diethylamino)-diazenolate-2-oxide (DEA) [25], the vitamin A ac-
tive derivative retinoic acid (RA) [26], or the organosulfur compound
DMSO [27]. Then, the appearance of beating foci in EBs was moni-
tored daily and the results obtained at DD9 are shown in Fig. 1A. It
is worth noting that the dose reported for each compound was cho-
sen from preliminary dose–response experiments (data not shown).
Among the compounds tested, only vitC treatment induced a sig-
niﬁcant increase in the appearance of beating foci in Fgfr1−/− EBs, al-
though with a lower extent when compared to Fgfr1+/− EBs that
spontaneously generate beating foci during differentiation.
In a second set of experiments, increasing concentrations of vitC and
of its oxidized form DHA were compared for their cardiomyogenic ac-
tivity in Fgfr1−/− mESC. As shown in Fig. 1B, both compounds were
able to rescue beating foci formation in a dose-dependent manner,
with maximal stimulation at 30μM (80% rescue) and 100μM (55% res-
cue) for vitC and DHA, respectively. In addition, a series of experiments
in which Fgfr1−/−mESC were treated with vitC at different time points
during the differentiation protocol showed that vitC administration at
DD0 and DD2 of the differentiation protocol was necessary and sufﬁ-
cient to induce the appearance of beating foci in Fgfr1−/− EBs (data
not shown).
3.2. Molecular analysis of vitC-treated Fgfr1−/− EBs
In order to conﬁrm that the beating cells observed during differenti-
ation of vitC-treated Fgfr1−/− mESC represent mature cardiomyocytes,
we analyzed the expression of early transcriptional (Nkx2.5) and late
structural (Myl2) cardiac gene markers. To this purpose, RNA was
extracted at different time points and analyzed by real time quantitative
PCR (qPCR). As shown in Fig. 2A, treatment of Fgfr1−/−mESCwith 30μM
vitC results in a signiﬁcant upregulation of bothNkx2.5 andMyl2 expres-
sion in respect to untreated mESC, while the expression of the endothe-
lial marker Vcam1 remains unchanged. qPCR results were conﬁrmed by
whole mount in situ hybridization experiments on EBs at DD9, probing
the expression of the structural cardiac proteinMyl2, and using the en-
dothelial marker Cdh5 as an internal control (Fig. 2B). As expected, vitC
treatment induces a signiﬁcant increase of Myl2-positive areas in
Fgfr1−/− EBs, while no modulation was observed for Cdh5 expression.
Moreover, immunohistochemical analysis of vitC-treated Fgfr1−/− EBs
shows a signiﬁcant increase in the expression of the cardiac structural
protein α-actin (Fig. 2B). Thus, vitC rescues cardiomyocyte formation
during Fgfr1−/−mESC differentiation process.
FGFR1 signaling plays important functions in mesoderm forma-
tion and development [28] and indeed, mesodermal genes are strong-
ly upregulated in Fgfr1−/−mESC [29]. In order to identify the target of
vitC intervention, modulation of Brachyury(T) gene expression during
the ﬁrst phases of mESC differentiation was evaluated. As shown in
Fig. 2C, vitC treatment of Fgfr1−/− mESC slightly downregulates
Brachyury(T), without bringing its expression back to the heterozy-
gous level.
Fig. 1. Effect of several compounds on beating foci formation during Fgfr1−/− EBs differentiation. A. Fgfr1−/−mESC were stimulated at DD0 and DD2 with the indicated compounds
and subjected to a standard differentiation protocol. The percentage of EBs with spontaneously contracting foci was counted at DD9 under an inverted microscope. Data represent
the mean of at least three independent experiments. B. Fgfr1−/− mESC were stimulated at DD0 and DD2 with different doses of vitC and its oxidized form DHA. The percentage of
EBs with spontaneously contracting foci was counted at DD9 under an inverted microscope. Data represent the mean of three independent experiments.
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Ascorbic acid is an hormetic molecule acting as a strong antioxidant
compound that reduces the oxidative indices after ischemia/reperfusion
[30,31] or as a pro-oxidantmolecule by generating cytotoxic amounts of
H2O2 under deﬁned experimental conditions [32,33]. Accumulating ev-
idences point to an important role for ROS as signaling molecules
during cardiomyocyte differentiation in mESC. Indeed, mechanical
strain-induced cardiovascular differentiation depends on ROS gen-
eration [34] and low levels of hydrogen peroxide stimulate car-
diomyogenesis of mESC [35].
On this basis, we assessed the possibility that vitC may rescue car-
diomyocyte differentiation in Fgfr1−/− mESC via modulation of the
intracellular redox state. To this purpose, the levels of intracellular
ROS and SOD activity were measured in differentiating EBs generated
by Fgfr1+/− and Fgfr1−/− mESC in the absence or in the presence of
vitC treatment.
In a ﬁrst set of experiments, mESC were labeled with the
ROS-sensitive indicator H2DCF-DA and the generation of oxidized
ﬂuorescent DCF was monitored daily by ﬂow cytometry until
DD4. As shown in Table 1, a progressive enhancement of ROS formation
was observed at DD3 and DD4 in both heterozygous and homozygous
Fgfr1 knockout EBs, showing a higher increase at DD4 for Fgfr1−/− EBs
in comparison with heterozygous cells. VitC addition to Fgfr1−/−mESC
prevented such increase, thus suggesting that vitC acts as an antioxidant
compound in the mESC system. To conﬁrm these observations, ROSFig. 2. VitC-induced cardiomyocyte formation during differentiation of Fgfr1−/− mESC. A. qP
Fgfr1+/−, Fgfr1−/− and vitC-treated Fgfr1−/− EBs at DD9. Equivalent amounts of cDNA were
paring differentiated cells to corresponding undifferentiated cells. Data are representative
Fgfr1+/−, Fgfr1−/− and vitC-treated Fgfr1−/− EBs were collected at DD9 and subjected to eit
nostained using an anti-α-actin antibody (ACTA1/ACTC1). C. Brachyury(T) expression during
at different DD, total RNA was extracted, and retrotranscribed. Equivalent amounts of cDNA
comparing differentiated cells to corresponding undifferentiated cells. Data are representatlevels were measured also in v-wt-hFGFR1 EBs in which cardiomyocyte
development was rescued by FGFR1 lentiviral transduction in Fgfr1−/−
mESC [36]. Again, an increment in ROS formation was observed from
DD3, reaching values higher than those measured in Fgfr1−/− EBs at
DD4. Thus, no relationship appears to exist between ROS levels and
cardiomyogenic activity in mESC.
The cellular levels of ROS are controlled by different enzymatic
and non-enzymatic antioxidant systems. In particular, vitC modulates
superoxide dismutase (SOD) activity [37]. Also, DCF dependent ﬂuo-
rescence may reﬂect relocation to the cytosol of lysosomal iron and/
or mitochondrial cytochrome c rather than intracellular ROS content
[38]. On this basis, we measured the SOD activity of differentiating
Fgfr1+/− and Fgfr1−/− EBs (Fig. 3A). Fgfr1+/− EBs showed a progres-
sive enhancement of SOD activity from DD2 until DD4, while no sig-
niﬁcant increment was observed in Fgfr1−/− mESC. In agreement
with previous observations [37], treatment of Fgfr1−/− EBs with
vitC downregulates intracellular SOD activity, thus conﬁrming the an-
tioxidant activity of vitC in this system. Again, these data suggest that
mESC cardiomyogenesis is independent of the modulation of redox
homeostasis.
The ROS-generating NADPH oxidase Nox4 is the main Nox isoform
expressed in mESC [39] and Nox4 expression is signiﬁcantly elevated
by vitC in mESC differentiated in low glucose medium [35]. As shown
in Fig. 3B, Nox4 expression progressively increases during EBS differ-
entiation of both Fgfr1+/− and Fgfr1−/− EBs, peaking at DD7 to de-
crease thereafter. Such increase was somehow reduced from DD4CR analysis of the expression of lineage markers in EBs. Total RNA was extracted from
ampliﬁed by qPCR and gene expression levels were quantiﬁed using REST [19], by com-
of at least two independent experiments. B. Cardiac marker expression in whole EBs.
her whole mount in situ hybridization using Myl2 and Cdh5 antisense probes or immu-
differentiation of EBs. Fgfr1+/−, Fgfr1−/− and vitC-treated Fgfr1−/− EBs were collected
were ampliﬁed by qPCR and gene expression levels were quantiﬁed using REST [19], by
ive of at least two independent experiments.
Table 1
Geo means of intracellular DCF ﬂuorescence.
DD2 DD3 DD4
Fgfr1+/− 12.8±2.1 15.5±1.7 13.8±1.8
Fgfr1−/− 11.4±2.3 14.7±1.1 16.6±1.5
Fgfr1−/−+vitC 10.3±1.3 10.7±1.3 11.3±1.2
v-wt-hFGFR1 9.6±1.9 14.8±1.3 17.0±1.1
Fgfr1+/−, Fgfr1−/−, vitC-treated Fgfr1−/−, and v-wt-hFGFR1 EBs were incubated with
H2DCF-DA for 30min at the indicated days of differentiation (DD). After extensive
washing, EBs were separated into single cell suspension and intracellular DCF ﬂuores-
cence was assayed by ﬂow cytometry. The reported values represent intensity mean of
two independent experiments.
144 E. Crescini et al. / Biochimica et Biophysica Acta 1833 (2013) 140–147onwards by vitC treatment of Fgfr1−/−mESC, thus indicating the lack
of any correlation between Nox4 expression and cardiomyocyte for-
mation in mESC.
Taken together, all the data point to the absence of a signiﬁcant cor-
relation between vitC modulation of intracellular redox state and car-
diomyocyte formation during Fgfr1−/− mESC differentiation. Indeed, at
variance with vitC and similar to the antioxidant retinoic acid (Fig. 1A),
the antioxidant compounds vitamin E, sodium metabisulﬁte (Na2S2O5),
N-acetylcysteine (NAC), and glutathione (GSH)were all unable to rescue
cardiomyocyte formation in Fgfr1−/− EBs (Fig. 3C). Thus, the antioxidant
activity of vitC does not appear to play any role in cardiomyocyte differ-
entiation in Fgfr1−/− EBs.3.4. VitC as a modulator of pluripotency genes in Fgfr1−/− mESC
Murine somatic cells can be reprogrammed to induced pluripotent
stem cells (iPSC) by retrovirus-mediated transduction of deﬁned
transcription factors, including Oct3/4, Sox2, and Klf4, followed by se-
lection for Fbx15 expression [40]. When compared to ES cells, these
iPSC showed different gene expression and DNAmethylation patterns
and did not contribute to adult chimeras [40]. At variance, selection of
transduced cells for Nanog rather than Fbx15 expression resulted in
high-quality iPSC comparable to ES cells in terms of morphology, pro-
liferation, teratoma formation, gene expression and competency for
adult chimeras [41].
VitC treatment of porcine blastocysts upregulates the expression
of Oct4, Sox2 and Klf4 [42], the latter acting as a transcriptional repres-
sor of p53 [43]. Indeed, vitC enhances iPSC generation from both
mouse and human somatic cells, acting, at least in part, by reducing
p53 levels [44].Fig. 3. VitC-mediated modulation of intracellular redox state. A. SOD activity. Fgfr1+/−, Fgfr1
for their capacity to inhibit autoxidation of epinephrine. Data are expressed as percentage
dependent experiments. B. qPCR analysis of Nox4 expression. Total RNA was extracted from F
amounts of cDNA were ampliﬁed by qPCR and gene expression levels were quantiﬁed usin
Data are representative of two independent experiments. C. Fgfr1−/− mESC were stimulated
tiation protocol. The percentage of EBs with spontaneously contracting foci was counted at
dent experiments.Previous observations had shown that Oct4 is properly down-
regulated in both Fgfr1+/− and Fgfr1−/− mESC at DD7 and later time
points of differentiation [16]. Since vitC exerts its cardiomyogenic res-
cue actionwhen administered during the very early phases of the differ-
entiation process (DD0 and DD2), we analyzed by qPCR the expression
of Oct4, Sox2, Klf4, and Nanog immediately for the ﬁrst 48 after removal
of LIF from the mESC culture medium and the data were compared to
those measured in undifferentiated cells (Fig. 4).
Undifferentiated Fgfr1+/− and Fgfr1−/−mESC express similar levels
of Oct4 and Sox2 transcripts whereas Klf4 and Nanog mRNA content
was approximately two-fold higher in Fgfr1−/− mESC (asterisks in
Fig. 4), thus suggesting amodulation of their expression by Fgfr1 signal-
ing. Following LIF removal, differentiating Fgfr1+/−mESC were charac-
terized by the upregulation of Oct4 and Sox2 expression and the
downregulation of Nanog and Kﬂ4 transcript levels, each gene showing
speciﬁc kinetics of expression. When compared to Fgfr1+/− cells, differ-
entiating Fgfr1−/−mESC showed similar kinetics of Oct4 expression but
differed for the other genes investigated (higher transcript levels for
Nanog and Klf4 and reduced levels for Sox2). However, vitC did not in-
duce a pattern of gene expression in Fgfr1−/− mESC similar to that
observed in Fgfr1+/− cells. Indeed, vitC treatment decreased the ex-
pression of Oct4 and Nanog in Fgfr1−/− mESC at 24h of differentia-
tion with no signiﬁcant effect on Sox2 and Kﬂ4, the latter gene
being downregulated by vitC treatment only at 48h. Similar results
were obtained with a second, independent clone of Fgfr1−/− mESC
(data not shown).
Next, we analyzed the impact of vitC on p53 levels in mESC. No
differences in either p53 protein levels or in the expression of p53 tar-
get genes, such as Spp1 and GADD45, were detected following vitC
treatment of Fgfr1−/− EBs (data not shown).
3.5. VitC as a cofactor of prolyl hydroxylase in Fgfr1−/− mESC
Ferrous iron-dependent hydroxylation by prolyl hydroxylase (PHD)
contributes to hypoxia inducible factor (HIF)-1α degradation in an ox-
ygenate environment [45]. Previous observations have shown that
vitC maintains the iron in a reduced state, thus acting as a PHD cofactor
[46].
We examined HIF-1α levels in undifferentiated and vitC-treated
mESC and found that Fgfr1−/− mESC have higher basal content of
HIF-1α, as judged by both mRNA and nuclear protein content (Fig. 5A).
In addition, a 24h vitC treatment of mESC slightly enhances HIF-1α nu-
clear immunoreactivity in both lines, independent of the presence of
FGFR1 (Fig. 5A). Since the quantiﬁcations using either ImageJ (NIH) or−/− and vitC-treated Fgfr1−/− EBs were collected at the indicated DD, lysed, and tested
of SOD activity measured in undifferentiated cells. Data are representative of three in-
gfr1+/−, Fgfr1−/− and vitC-treated Fgfr1−/− EBs at the indicated time points. Equivalent
g REST [19], by comparing differentiated cells to corresponding undifferentiated cells.
at DD0 and DD2 with the indicated compounds and subjected to a standard differen-
DD9 under an inverted microscope. Data represent the mean of at least three indepen-
Fig. 4. VitC-induced pluripotent gene modulation during differentiation of Fgfr1−/− mESC. qPCR analysis of the expression of Oct4 (A), Nanog (B), Sox2 (C), and Klf4 (D). LIF was
removed from culture medium and cells were stimulated or not with 50μM vitC. Total RNA was extracted from Fgfr1+/−, Fgfr1−/− and vitC-treated Fgfr1−/− EBs at the indicated
time points. Equivalent amounts of cDNA were ampliﬁed by qPCR and gene expression levels were quantiﬁed using REST [19], by comparing differentiated cells to Fgfr1+/−
undifferentiated cells. Data are representative of at least two independent experiments. The relative mRNA levels in undifferentiated Fgfr1−/−mESC in respect to undifferentiated
Fgfr1+/− mESC are represented by the asterisk on the Y axis.
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ble amount of nuclear HIF-1α in Fgfr1−/− vs Fgfr1+/−mESC,wewent fur-
ther to elucidate this issue. We treated Fgfr1−/−mESC with the reduced
form of iron (FeCl2) or CAY10585, an inhibitor of the accumulation and
of the transcriptional activity of HIF-1α [17]. Treatments followed theFig. 5. HIF-1α-related modulation of cardiomyocyte differentiation in Fgfr1−/− EBs. A. HIF-1
while nuclear HIF-1α protein was evaluated in heterozygous and homozygous mESC, follow
three independent experiments B. Fgfr1−/−mESC were stimulated at DD0 and DD2 with the
age of EBs with spontaneously contracting foci was counted at DD9 under an invertedmicrosco
the expression of lineage markers in EBs. Total RNA was extracted from Fgfr1+/−, Fgfr1−/−, FeC
ﬁed by quantitative PCR and gene expression levels were quantiﬁed using REST [19], by compa
least two independent experiments.same schedule as vitC, starting at LIF removal and repeated two days
later. Beating foci appearance was monitored daily and the results at
DD9 demonstrate that, similar to vitC, both FeCl2 and CAY10585 rescue
cardiomyocyte development in Fgfr1−/−EBs, as shownby the appearance
of beating foci (Fig. 5A) and expression of cardiac gene markers (Fig. 5B).αmRNA levels were assessed in undifferentiated mESC by qPCR analysis (upper panel),
ing a 24h treatment with 50μM vitC (lower panel). The same result was obtained in
indicated compounds and subjected to a standard differentiation protocol. The percent-
pe. Data represent themean of at least three independent experiments. C. qPCR analysis of
l2-, and CAY10585-treated Fgfr1−/− EBs at DD9. Equivalent amounts of cDNAwere ampli-
ring differentiated cells to the relative undifferentiated state. Data are representative of at
146 E. Crescini et al. / Biochimica et Biophysica Acta 1833 (2013) 140–1474. Discussion
Embryonic stem cells are a powerful tool to study the impact of
speciﬁc gene inactivation during development also for those
loss-of-function mutations resulting in early embryonic lethality,
such as FGFR1. The mechanism by which the absence of FGFR1 does
not allow cardiomyocyte development in the mESC system is poorly
understood. Previous observations from our laboratory had shown
the impairment of early mesodermal gene expression in Fgfr1−/−
EBs at DD3/4 [29], followed by the lack of Nkx2.5 upregulation at
DD5 [36], thus suggesting that FGFR1 is required within the ﬁrst
days of mESC differentiation.
Various extrinsic factors can promote cardiogenesis in themESC sys-
tem, including a variety of chemical compoundswith different, not fully
characterized mechanisms of action [22]. In the present work various
cardiomyocyte-enhancing molecules were assessed for their ability to
rescue cardiomyocyte development in Fgfr1−/−mESC. The results dem-
onstrate that, among themolecules tested, only vitC was able to restore
beating foci appearance and cardiac gene expression at bothmRNA and
protein levels, thus indicating a functional recovery of cardiomyocyte
development after Fgfr1 knockdown. The appearance of beating foci in
Fgfr1−/− EBs could be obtained also by treatment with the oxidized
form of vitC, DHA, although with a lower efﬁciency, probably due to
its instability in solution [47].
It should be noticed that vitC can recover also the absence of car-
diomyocyte differentiation in EphB4 knockout EBs [48], thus suggesting
that the compound is acting downstream of both FGFR1 and EphB4,
supposedly in a commonpathway that leads to cardiomyocyte develop-
ment. Although we did not observe any modulation of EphB4 expres-
sion in vitC-treated Fgfr1−/− EBs (data not shown), transactivation
between members of the FGFR and ephrin receptor families has
been demonstrated following the direct contact between their cyto-
plasmic domains [49]. Further experiments are required to elucidate
this issue.
VitC is a multifaceted molecule acting as a cofactor in several enzy-
matic reactions [50,51]. In order to identify which of its properties is re-
sponsible for cardiomyocyte differentiation rescue in Fgfr1−/− EBs, we
initially investigated the capacity of vitC to affect the intracellular
redox state of mESC by evaluating the modulation of ROS content,
SOD activity, and Nox4 expression. VitC treatment reduced all these pa-
rameters in Fgfr1−/− EBs, thereby suggesting that vitC can indeed affect
the redox state of the mESC system. However, the different levels of
ROS, SOD, and Nox4 measured in Fgfr1+/−, Fgfr1−/−, vitC-treated
Fgfr1−/−, and hFGFR1-overexpressing Fgfr1−/− EBs did not correlate
with their different cardiomyogenic ability during the differentiation
process. These observations, together with the incapacity of various
well-known antioxidant molecules to mimic the cardiomyogenic activ-
ity of vitC in Fgfr1−/−mESC, rule out the possibility that the antioxidant
activity of vitC plays a role in mediating cardiomyocyte formation
downstream of FGFR1.
Next, we analyzed the hypothesis that vitC could overcome Fgfr1
loss-of-function through modulation of pluripotency genes and/or their
main target protein p53.We showed that Fgfr1 knockout doubles the ex-
pression levels of Klf4 and Nanog in undifferentiated Fgfr1−/− mESC as
compared to their heterozygous counterpart. Following LIF removal, dif-
ferentiating Fgfr1+/− and Fgfr1−/− mESC showed a different pattern of
expression of the pluripotency genes Nanog, Klf4 and Sox2 and a similar
Oct4 expression. However, vitC did not restore a pattern of gene expres-
sion in Fgfr1−/− mESC similar to that observed in Fgfr1+/− cells. Thus,
none of the differences in Oct4, Sox2, Kﬂ4, and/or Nanog expression
observed between Fgfr1+/− and Fgfr1−/− mESC in the absence or
in the presence of vitC treatment appears to parallel the reduced
cardiomyogenic ability of Fgfr1−/−mESC and explain the cardiomyogenic
rescuing capacity exerted by vitC in these cells. In addition, vitC treatment
did not affect p53 protein levels and the expression of the p53 target
genes Spp1 and GADD45 in Fgfr1−/−mESC (data not shown).Our data indicate that the lack of cardiomyocyte development in
Fgfr1−/− EBs can be rescued by addition of vitC, Fe2+, or the HIF-1α
inhibitor CAY10585 during the ﬁrst steps of the differentiation pro-
cess. Of note, other divalent metals, such as cadmium, copper, or
zinc, were ineffective (data not shown).
Fgfr1−/− mESC generate a large amount of mesodermal cells and
vitC addition, that does not change signiﬁcantly the expression of
Brachyury(T), effectively allows the following differentiation of
Nkx2.5+ cardiac progenitor cells. Further experiments using dif-
ferent models are required to elucidate this issue. Although these
results do not rule out other mechanisms of action, our observations
point to HIF-1α modulation as a crucial step in FGFR1-dependent car-
diomyogenesis. To our knowledge, no correlations exist between the
presence/activation of FGFR1 and HIF-1α level modulation, although
it has been reported that HIF-1α is required for Nkx2.5 upregulation in
Xenopus heart development [52] as well as Fgfr1 that is needed to
upregulateNkx2.5 inmESC [16]. Therefore, it is tempting to hypothesize
that FGFR1 acts as a controller of HIF-1α level during the ﬁrst phases of
development, where hypoxia plays a fundamental role for heart forma-
tion [53]. The maintenance of a basal HIF-1α level in Fgfr1+/− mESC,
possibly restored in Fgfr1−/− mESC by the increase of PHD activity or
by HIF-1α inhibition, will allow the following boost necessary for
Nkx2.5 upregulation in cardiovascular progenitor cells.
5. Conclusions
In conclusion, our data demonstrate that vitC, FeCl2, and the
HIF-1α inhibitor CAY10585 rescue cardiomyocyte differentiation
due to the genetic defect of Fgfr1−/− mESC. We extend previous ob-
servations about the cardiomyogenic properties of vitC and suggest
that modulation of HIF-1α may mediate the effect of Fgfr1 on car-
diomyogenesis during mESC differentiation.
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